Literature DB >> 20193684

Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis.

Markus Mair1, Gernot Zollner, Doris Schneller, Monica Musteanu, Peter Fickert, Judith Gumhold, Christian Schuster, Andrea Fuchsbichler, Martin Bilban, Stefanie Tauber, Harald Esterbauer, Lukas Kenner, Valeria Poli, Leander Blaas, Jan Wilhelm Kornfeld, Emilio Casanova, Wolfgang Mikulits, Michael Trauner, Robert Eferl.   

Abstract

BACKGROUND & AIMS: Signal transducer and activator of transcription 3 (Stat3) is the main mediator of interleukin-6-type cytokine signaling required for hepatocyte proliferation and hepatoprotection, but its role in sclerosing cholangitis and other cholestatic liver diseases remains unresolved.
METHODS: We investigated the role of Stat3 in inflammation-induced cholestatic liver injury and used mice lacking the multidrug resistance gene 2 (mdr2(-/-)) as a model for SC.
RESULTS: We show that conditional inactivation of Stat3 in hepatocytes and cholangiocytes (stat3(Deltahc)) of mdr2(-/-) mice strongly aggravated bile acid-induced liver injury and fibrosis. A similar phenotype was observed in mdr2(-/-) mice lacking interleukin-6 production. Biochemical and molecular characterization suggested that Stat3 exerts hepatoprotective functions in both hepatocytes and cholangiocytes. Loss of Stat3 led to increased expression of tumor necrosis factor alpha, which might reduce the barrier function of bile ducts. Moreover, Stat3-deficient hepatocytes displayed up-regulation of bile acid biosynthesis genes and down-regulation of hepatoprotective epidermal growth factor receptor and insulin-like growth factor 1 signaling pathways. Consistently, stat3(Deltahc) mice were more sensitive to cholic acid-induced liver damage than control mice.
CONCLUSIONS: Our data suggest that Stat3 prevents cholestasis and liver damage in sclerosing cholangitis via regulation of pivotal functions in hepatocytes and cholangiocytes. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193684     DOI: 10.1053/j.gastro.2010.02.049

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  37 in total

1.  Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway.

Authors:  Liu-Ya Tang; Mary Heller; Zhaojing Meng; Li-Rong Yu; Yi Tang; Ming Zhou; Ying E Zhang
Journal:  J Biol Chem       Date:  2017-01-31       Impact factor: 5.157

2.  Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.

Authors:  Tung-Hung Su; Chung-Wai Shiau; Ping Jao; Chen-Hua Liu; Chun-Jen Liu; Wei-Tien Tai; Yung-Ming Jeng; Hung-Chih Yang; Tai-Chung Tseng; Hsiang-Po Huang; Huei-Ru Cheng; Pei-Jer Chen; Kuen-Feng Chen; Jia-Horng Kao; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-26       Impact factor: 11.205

Review 3.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

Review 4.  STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver.

Authors:  Bin Gao; Hua Wang; Fouad Lafdil; Dechun Feng
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

5.  Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice.

Authors:  Fanli Meng; Kai Wang; Tomonori Aoyama; Sergei I Grivennikov; YongHan Paik; David Scholten; Min Cong; Keiko Iwaisako; Xiao Liu; Mingjun Zhang; Christoph H Österreicher; Felix Stickel; Klaus Ley; David A Brenner; Tatiana Kisseleva
Journal:  Gastroenterology       Date:  2012-06-08       Impact factor: 22.682

6.  RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation.

Authors:  Raymond S Oh; Andrew J Haak; Karry M J Smith; Giovanni Ligresti; Kyoung Moo Choi; Tiao Xie; Shaohua Wang; Paula R Walters; Michael A Thompson; Michelle R Freeman; Logan J Manlove; Vivian M Chu; Carol Feghali-Bostwick; Anja C Roden; Jürgen Schymeinsky; Christina M Pabelick; Y S Prakash; Robert Vassallo; Daniel J Tschumperlin
Journal:  J Cell Sci       Date:  2018-05-15       Impact factor: 5.285

7.  Characterization of acute biliary hyperplasia in Fisher 344 rats administered the indole-3-carbinol analog, NSC-743380.

Authors:  Sandy R Eldridge; Joseph Covey; Joel Morris; Bingliang Fang; Thomas L Horn; Karen E Elsass; John R Hamre; David L McCormick; Myrtle A Davis
Journal:  Toxicol Appl Pharmacol       Date:  2014-10-28       Impact factor: 4.219

8.  STAT3 Inhibition Suppresses Hepatic Stellate Cell Fibrogenesis: HJC0123, a Potential Therapeutic Agent for Liver Fibrosis.

Authors:  Omar Nunez Lopez; Fredrick J Bohanon; Xiaofu Wang; Na Ye; Tiziana Corsello; Yesenia Rojas-Khalil; Haijun Chen; Haiying Chen; Jia Zhou; Ravi S Radhakrishnan
Journal:  RSC Adv       Date:  2016-10-14       Impact factor: 3.361

9.  Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.

Authors:  Zhenhua Luo; Anil G Jegga; Jorge A Bezerra
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

10.  STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.

Authors:  Mesias Pedroza; Thuy T Le; Katherine Lewis; Harry Karmouty-Quintana; Sarah To; Anuh T George; Michael R Blackburn; David J Tweardy; Sandeep K Agarwal
Journal:  FASEB J       Date:  2015-08-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.